LOS ANGELES, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before January 16, 2026.

Microsoft is a top AI investment, benefiting from Azure's growth and deep enterprise AI integration. MSFT delivered strong revenue growth, with Azure accelerating to 40% YoY growth and robust performance in enterprise software segments. Trading at 29x earnings, MSFT offers a reasonable valuation, strong balance sheet, and potential for operating leverage and margin expansion.

Abercrombie & Fitch (NYSE:ANF) shares surged 28% after the clothing retailer reported strong results for the third quarter, surpassing Wall Street expectations on both earnings and revenue. Adjusted earnings per share (EPS) were $2.36, topping estimates of $2.16.

CyberArk (CYBR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

From a technical perspective, Lemonade (LMND) is looking like an interesting pick, as it just reached a key level of support. LMND recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

The heavy selling pressure might have exhausted for Pacasmayo (CPAC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Hecla Mining (HL) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HL crossed above the 20-day moving average, suggesting a short-term bullish trend.

Newmont Corporation (NEM) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, NEM broke through the 20-day moving average, which suggests a short-term bullish trend.

LTM surges on strong demand, efficiency gains and rising estimates, as passenger growth and premium upgrades lift momentum.

After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

While the top- and bottom-line numbers for Analog Devices (ADI) give a sense of how the business performed in the quarter ended October 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Newmont Corporation (NEM) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, NEM broke through the 50-day moving average, which suggests a short-term bullish trend.

The headline numbers for Abercrombie (ANF) give insight into how the company performed in the quarter ended October 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

While the top- and bottom-line numbers for Smucker (SJM) give a sense of how the business performed in the quarter ended October 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Although the revenue and EPS for Dick's (DKS) give a sense of how its business performed in the quarter ended October 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Celestica (CLS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, CLS broke through the 50-day moving average, which suggests a short-term bullish trend.